Literature DB >> 33861376

[Central serous chorioretinopathy].

Laurenz Pauleikhoff1, Hansjürgen Agostini1, Clemens Lange2.   

Abstract

Central serous chorioretinopathy (CSC) is the fourth most common disease of the macula after age-related macular degeneration, diabetic retinopathy and retinal vein occlusion and a cause of irreversible visual loss. This article gives an overview of the epidemiology, risk factors, pathophysiology, clinical presentation, multimodal imaging and discusses current therapeutic options for CSC.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Clinical presentation; Epidemiology; Multimodal imaging; Pathophysiology; Risk factors

Mesh：

Year:  2021        PMID： 33861376     DOI： 10.1007/s00347-021-01376-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  75 in total

Review 1.  Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.

Authors:  Alejandra Daruich; Alexandre Matet; Ali Dirani; Elodie Bousquet; Min Zhao; Nicolette Farman; Frédéric Jaisser; Francine Behar-Cohen
Journal:  Prog Retin Eye Res       Date:  2015-05-27       Impact factor: 21.198

2.  Endocrine abnormalities in patients with central serous chorioretinopathy.

Authors:  Robert Haimovici; Shimon Rumelt; James Melby
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  Central serous chorioretinopathy in women.

Authors:  D A Quillen; D M Gass; R D Brod; T W Gardner; G W Blankenship; J L Gottlieb
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

4.  Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.

Authors:  Min Zhao; Isabelle Célérier; Elodie Bousquet; Jean-Claude Jeanny; Laurent Jonet; Michèle Savoldelli; Olivier Offret; Antoine Curan; Nicolette Farman; Frédéric Jaisser; Francine Behar-Cohen
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

5.  The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells.

Authors:  Min Zhao; Fatemeh Valamanesh; Isabelle Celerier; Michèle Savoldelli; Laurent Jonet; Jean-Claude Jeanny; Frederic Jaisser; Nicolette Farman; Francine Behar-Cohen
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

6.  Corticosteroid-induced central serous chorioretinopathy.

Authors:  M Wakakura; E Song; S Ishikawa
Journal:  Jpn J Ophthalmol       Date:  1997 May-Jun       Impact factor: 2.447

7.  Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Elodie Bousquet; Talal Beydoun; Min Zhao; Leila Hassan; Olivier Offret; Francine Behar-Cohen
Journal:  Retina       Date:  2013 Nov-Dec       Impact factor: 4.256

8.  The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.

Authors:  Anna S Kitzmann; Jose S Pulido; Nancy N Diehl; David O Hodge; James P Burke
Journal:  Ophthalmology       Date:  2008-01       Impact factor: 12.079

Review 9.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

10.  Corticosteroids and central serous chorioretinopathy.

Authors:  Cynthia A Carvalho-Recchia; Lawrence A Yannuzzi; Silvana Negrão; Richard F Spaide; K Bailey Freund; Hanna Rodriguez-Coleman; Marcio Lenharo; Tomohiro Iida
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.